# VYNE Therapeutics Inc. (VYNE)

Source: https://www.quantisnow.com/company/VYNE
Generated: 2026-11-20T18:18:27.373Z

- Ticker: VYNE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001566044
- Website: vynetherapeutics.com

## About

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

## Latest VYNE news and filings

- 2026-10-30 20:04 UTC [SEC Form 4] [Chief Development Officer Payton Lori was granted 99,827 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-development-officer-payton-lori-was-granted-99827-stock-options-6765170)
- 2026-10-30 20:03 UTC [SEC Form 4] [Chief Operating Officer Alford Rachael was granted 89,844 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-alford-rachael-was-granted-89844-stock-options-6765165)
- 2026-10-30 20:02 UTC [SEC Form 4] [Chief Executive Officer Frey Rebecca was granted 465,857 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-frey-rebecca-was-granted-465857-stock-options-6765163)
- 2026-10-30 20:02 UTC [SEC Form 4] [Chief Medical Officer Ryder Steven was granted 113,137 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-ryder-steven-was-granted-113137-stock-options-6765161)
- 2026-10-30 20:01 UTC [SEC Form 4] [Chief Financial Officer Zeronda Tyler was granted 156,115 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-zeronda-tyler-was-granted-156115-stock-options-6765137)
- 2026-09-14 20:01 UTC [SEC Form 8-K] [VYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/vyne-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6714352)
- 2026-09-11 20:52 UTC [SEC Form 424B5] [SEC Form 424B5 filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-vyne-therapeutics-inc-6713218)
- 2026-09-11 20:44 UTC [SEC Form 424B5] [SEC Form 424B5 filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-vyne-therapeutics-inc-6713186)
- 2026-09-10 20:01 UTC [SEC Form 8-K] [VYNE Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyne-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6711490)
- 2026-08-20 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-vyne-therapeutics-inc-6689241)
- 2026-08-13 23:02 UTC [SEC Form POS AM filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-vyne-therapeutics-inc-6681624)
- 2026-08-13 20:14 UTC [SEC Form 8-K] [Amendment: VYNE Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure](https://www.quantisnow.com/insight/amendment-vyne-therapeutics-inc-filed-sec-form-8-k-results-of-6680626)
- 2026-08-13 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-vyne-therapeutics-inc-6680175)
- 2026-08-07 16:51 UTC [SEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-vyne-therapeutics-inc-6671200)
- 2026-08-06 01:08 UTC [SEC Form SCHEDULE 13D filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-vyne-therapeutics-inc-6666682)
- 2026-08-03 20:00 UTC [SEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-vyne-therapeutics-inc-6659500)
- 2026-07-30 20:05 UTC [SEC Form 4] [Large owner Rtw Fund Group Gp, Llc disposed of 133,290 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-rtw-fund-group-gp-llc-disposed-of-133290-6656076)
- 2026-07-30 20:03 UTC [SEC Form 8-K] [SEC Form 8-K filed by VYNE Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-vyne-therapeutics-inc-6655952)
- 2026-07-30 20:01 UTC [SEC Form 3] [New insider Rtw Fund Group Gp, Llc claimed ownership of 399,597 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-rtw-fund-group-gp-llc-claimed-ownership-of-6655942)
- 2026-07-30 01:36 UTC [SEC Form 4] [SEC Form 4 filed by Director Ashiya Mona](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ashiya-mona-6654523)
- 2026-07-30 01:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Zeronda Tyler](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-zeronda-tyler-6654515)
- 2026-07-30 01:26 UTC [SEC Form 3] [New insider Orbimed Advisors Llc claimed ownership of 266,306 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-orbimed-advisors-llc-claimed-ownership-of-266306-shares-6654511)
- 2026-07-30 01:21 UTC [SEC Form 3] [New insider Ashiya Mona claimed ownership of 266,306 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ashiya-mona-claimed-ownership-of-266306-shares-sec-6654509)
- 2026-07-30 01:20 UTC [SEC Form 3] [SEC Form 3 filed by new insider White William Richard](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-white-william-richard-6654508)
- 2026-07-30 01:17 UTC [SEC Form 3] [SEC Form 3 filed by new insider Silverman Peter B.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-silverman-peter-b-6654506)
- 2026-07-30 01:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lundberg Sven Ante](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lundberg-sven-ante-6654504)
- 2026-07-30 01:11 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hoerter Steven L.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hoerter-steven-l-6654501)
- 2026-07-30 01:08 UTC [SEC Form 3] [SEC Form 3 filed by new insider Alford Rachael](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-alford-rachael-6654499)
- 2026-07-30 01:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Payton Lori](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-payton-lori-6654496)
- 2026-07-30 01:03 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ryder Steven](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ryder-steven-6654494)
- 2026-07-30 01:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Frey Rebecca](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-frey-rebecca-6654493)
- 2026-07-29 20:11 UTC [SEC Form 3] [New insider Perceptive Advisors Llc claimed ownership of 266,309 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-perceptive-advisors-llc-claimed-ownership-of-266309-shares-6653730)
- 2026-07-28 21:11 UTC [SEC Form 8-K] [VYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyne-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6652102)
- 2026-07-24 21:00 UTC [SEC Form 4] [CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 23% to 74,918 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-financial-officer-zeronda-tyler-covered-exercisetax-liability-with-22516-6648580)
- 2026-07-24 21:00 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 15,405 shares, decreasing direct ownership by 14% to 95,944 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-scientific-officer-stuart-iain-covered-exercisetax-liability-with-15405-6648579)
- 2026-07-24 21:00 UTC [SEC Form 4] [PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 79,391 shares, decreasing direct ownership by 19% to 347,174 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/president-and-ceo-domzalski-david-covered-exercisetax-liability-with-79391-6648578)
- 2026-07-24 21:00 UTC [SEC Form 4] [CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 19% to 95,918 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-legal-officer-and-gc-harsch-mutya-covered-exercisetax-liability-6648577)
- 2026-07-23 20:26 UTC [Dividends] [VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience](https://www.quantisnow.com/insight/vyne-therapeutics-provides-update-regarding-cash-dividend-reverse-stock-split-6647235)
- 2026-07-21 12:14 UTC [SEC Form 8-K] [VYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vyne-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6643343)
- 2026-07-21 12:00 UTC [Dividends] [VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience](https://www.quantisnow.com/insight/vyne-therapeutics-announces-1-for-50-reverse-stock-split-and-provides-update-6643211)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VYNE
- Earnings history: https://www.quantisnow.com/earnings/VYNE
- Dividend history: https://www.quantisnow.com/dividends/VYNE
- Insider transactions: https://www.quantisnow.com/insiders/VYNE
- Options chain: https://www.quantisnow.com/options/VYNE
- SEC 8-K filings only: https://www.quantisnow.com/company/VYNE/8-k
- RSS and alerts for VYNE: https://www.quantisnow.com/docs/rss-feeds.md
